MSH2 and rectum adenocarcinoma: In bladder urothelial carcinoma (BLCA), BRCA, cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), HNSC, kidney chromophobe (KICH), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), uterine corpus endometrial carcinoma (UCEC) (P value <0.001), LGG, and thyroid carcinoma (THCA) (P value <0.05), the tumors in TCGA cohort did not show MSH2 expression levels lower than those of the relevant control normal tissues.